Eupraxia Pharmaceuticals
EPRX
8 hedge funds and large institutions have $4.43M invested in Eupraxia Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.85% more ownership
Funds ownership: 0% → 4.85% (+4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$3.8M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$739K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$137K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$82.3K |
| 5 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
+$36.2K |
Top Sellers
EPRX Hedge Fund Activity: Q2 2024 in Review
8 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q2 2024, worth a combined $4.43M.
Buyers outnumbered sellers: 8 funds opened new EPRX positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Scotia Capital, opening a new position worth an estimated $3.8M.
- 8 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q2 2024, up from 0 in Q1 2024.
- Funds reported $4.43M of Eupraxia Pharmaceuticals stock for Q2 2024.
- 8 funds opened new Eupraxia Pharmaceuticals positions in Q2 2024 and 0 closed out, a net change of +8 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q2 2024 was Scotia Capital, an estimated $3.8M added.
Based on aggregated 13F filings for Q2 2024.